Class summary at a glance.

Every drug in the Androgen Receptor Inhibitor class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $5.85Bcombined across class
Total Rx claims: 747K199K unique beneficiaries
Generic mfrs (active): 8across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Enzalutamide

Brand: Xtandi · 433K Part D claims (CY24) · 75K beneficiaries · First FDA approval: 2012-08-31

Brand-only (no generics) 981 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $5.84B

Class share

100%

of class CY24 spend

View profile →

Bicalutamide

Brand: CASODEX · 310K Part D claims (CY24) · 123K beneficiaries · First FDA approval: 1995-10-04

6 generic mfrs 0 plans require PA

Low NADAC$0.403

→

Avg plan cost$0.403

Part D spend $10.9M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Clascoterone

Brand: Winlevi · 3K Part D claims (CY24) · 1K beneficiaries · First FDA approval: 2021-10-04

Brand-only (no generics)

Low NADAC$9.99

→

Avg plan cost$9.99

Part D spend $1.7M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Nilutamide

Brand: Nilandron · 406 Part D claims (CY24) · 78 beneficiaries · First FDA approval: 2013-07-15

1 generic mfrs 37 plans require PA Discontinued

Low NADAC—

→

Avg plan cost—

Part D spend $1.4M

Class share

of class CY24 spend

View profile →

Flutamide

Brand: Eulexin · 67 Part D claims (CY24) · 20 beneficiaries · First FDA approval: 2021-11-12

1 generic mfrs 43 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $216500

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.